Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system selectively destroys the insulin-producing beta cells in the pancreatic islets. This leads to absolute insulin deficiency, requiring lifelong exogenous insulin therapy to manage blood glucose levels and prevent life-threatening complications. Despite advances in insulin analogs, continuous glucose monitors, and insulin pumps, patients still face significant burdens, including the risk of hypoglycemia, long-term microvascular and macrovascular complications, and a reduced quality of life. The search for a definitive cure or a therapy that can restore endogenous insulin production in a durable, safe manner has driven intense research into immunomodulatory and regenerative strategies. Among these, cell-based immunotherapy has emerged as one of the most promising frontiers, offering the potential to re-establish immune tolerance, protect transplanted beta cells, or generate new insulin-producing cells from stem cell sources. This article provides an in-depth overview of the emerging approaches in cell-based immunotherapy for type 1 diabetes, highlighting the scientific rationale, key technologies, clinical progress, and the challenges that lie ahead.

The Rationale for Cell-Based Immunotherapy in T1D

The central pathophysiological defect in T1D is the loss of self-tolerance to pancreatic beta cell antigens. Autoreactive T cells, particularly CD4+ and CD8+ T cells, escape thymic deletion and peripheral regulation, leading to insulitis and progressive beta cell destruction. B cells and innate immune cells also contribute to the autoimmune process. Current insulin therapy is merely substitutive; it does not address the underlying immune attack. Cell-based immunotherapy aims to directly modify the immune system's behavior or to provide a renewable source of beta cells that are either inherently resistant to autoimmune assault or protected by immunomodulatory cells or devices.

The two main pillars of cell-based immunotherapy for T1D are: (1) cellular immunomodulation—using immune cells such as regulatory T cells (Tregs), tolerogenic dendritic cells (tolDCs), or mesenchymal stromal cells (MSCs) to suppress or reprogram the autoimmune response; and (2) beta cell replacement—transplanting beta cells derived from stem cells (e.g., embryonic stem cells or induced pluripotent stem cells) that are either encapsulated in biomaterials or combined with immunomodulatory therapies to prevent rejection and recurrence of autoimmunity. Increasingly, these two pillars are being combined into hybrid strategies, such as engineering beta cells to express immune checkpoint proteins or co-transplanting them with Tregs. The ultimate goal is to achieve sustained insulin independence without chronic immunosuppression.

Regulatory T Cell (Treg) Therapy: Restoring Immune Balance

The Biology of Tregs

Regulatory T cells are a specialized subset of CD4+ T cells that express the transcription factor FoxP3 and the high-affinity IL-2 receptor alpha chain (CD25). They play a critical role in maintaining immune homeostasis by suppressing the activation and effector functions of autoreactive T cells. In T1D, both the frequency and function of Tregs are reported to be defective, allowing pathogenic clones to proliferate. Treg therapy seeks to increase the number and/or enhance the suppressive capacity of these cells in patients, thereby tipping the balance towards tolerance. Autologous Tregs are isolated from the patient’s blood, expanded ex vivo to large numbers (often using anti-CD3/anti-CD28 beads and high-dose IL-2), and then reinfused. Alternatively, antigen-specific Tregs can be engineered by transducing them with chimeric antigen receptors (CAR-Tregs) that recognize beta cell antigens, enabling targeted suppression at the site of inflammation.

Clinical Progress with Treg Therapeutics

Several Phase 1 and Phase 2 clinical trials have demonstrated the safety and preliminary efficacy of polyclonal Treg infusion in recent-onset T1D patients. A landmark trial by the T1DAL study group (NCT01210664) showed that a single infusion of autologous Tregs was well-tolerated and resulted in preserved C-peptide levels in a subset of patients over two years. The Caladrius Biosciences (Caladrius) trial (NCT02773979) used antigen-specific Tregs expanded with an anti-CD3-based manufacturing process, showing signals of metabolic benefit. More recently, CAR-Tregs targeting insulin peptide-MHC complexes have been tested in preclinical models with encouraging results, and first-in-human trials are likely on the horizon. However, challenges remain in manufacturing standardization, maintaining Treg stability in vivo (avoiding conversion to pro-inflammatory phenotypes), and optimizing dosing. Combining Treg therapy with low-dose IL-2 or other immunomodulators is being actively explored to support Treg persistence and function.

Stem Cell–Derived Beta Cells: Toward a Renewable Supply

From Directed Differentiation to Transplantable Islets

The ability to generate functional, glucose-responsive insulin-producing cells from human pluripotent stem cells (hPSCs) has been a game-changer in diabetes research. Directed differentiation protocols, pioneered by researchers such as Doug Melton (Harvard) and companies like ViaCyte (now Vertex Pharmaceuticals), have evolved from generating immature pancreatic progenitors to producing cells that closely resemble bona fide beta cells (stem cell–derived islets, or SC-islets). These SC-islets express key markers (PDX1, NKX6.1, insulin, glucagon), secrete insulin in response to glucose stimulation, and reverse diabetes in immunodeficient mice. Vertex’s VX-880 (now VX-264) is a notable clinical candidate: fully differentiated SC-islets are transplanted into patients via portal vein infusion, combined with standard immunosuppression. Preliminary results from Phase 1/2 trials (NCT04786262) demonstrated robust C-peptide production and insulin independence in some patients, generating significant excitement.

Encapsulation and Immune Evasion

To avoid the need for systemic immunosuppression, researchers have developed encapsulation devices that create a physical barrier between transplanted cells and the host immune system. Macroencapsulation devices like ViaCyte’s PEC-Encap (NCT02939118) contain differentiated pancreatic progenitors in a semipermeable membrane that allows oxygen and nutrients in and insulin out, while keeping immune cells away. However, early trials showed only limited graft survival and insulin output, partly due to foreign body reactions and insufficient oxygenation. Microencapsulation using alginate hydrogels has been refined to reduce fibrosis and improve biocompatibility. Next-generation strategies involve genetic engineering of SC-islets to evade immune recognition. For example, knocking out HLA class I molecules (β2-microglobulin) and overexpressing immune checkpoint proteins such as PD-L1 or CD47 can make the cells “invisible” to the immune system. Vertex’s VX-264 uses such an immune-evasive platform, allowing transplantation without immunosuppression. Early clinical data for VX-264 are awaited with anticipation.

Innovative Strategies to Overcome Immune Rejection

Gene Editing with CRISPR/Cas9

CRISPR/Cas9 has unlocked precise genetic modifications to create “universal donor” stem cell–derived cells and engineer immune cells with enhanced function. For beta cell replacement, multiple edits can be introduced simultaneously: knockout of HLA-A, HLA-B, and HLA-C (HLA class I) to prevent CD8+ T cell recognition; knockout of CIITA to eliminate HLA class II expression; and insertion of molecules that inhibit NK cells (e.g., HLA-E, HLA-G) and macrophages (CD47). Such hypoimmunogenic SC-islets have been successfully transplanted into allogeneic recipients without immunosuppression in several preclinical models. For Treg therapy, CRISPR can be used to generate antigen-specific CAR-Tregs with improved stability and homing to the pancreas. The technology also allows the creation of “off-the-shelf” allogeneic Treg products that could be mass-produced and administered to any patient, dramatically lowering cost and wait times.

Biomaterials and Advanced Encapsulation

Beyond simple alginate capsules, innovations in biomaterials are enabling better integration and function of encapsulated cells. Macroporous scaffolds provide space for vascularization, improving oxygen and nutrient delivery. Hydrogels incorporating growth factors or immunomodulatory molecules can create a local tolerogenic environment. “Smart” encapsulation systems use responsive polymers that release insulin in a glucose-dependent manner, mimicking natural beta cell function. Another cutting-edge approach is the development of “cryogel” scaffolds that can be injected subcutaneously, allowing for easier retrieval and monitoring. Research on the foreign body response has led to coatings that resist fibrosis, such as triazole-modified alginate and zwitterionic polymers. These advances are critical for the long-term survival of encapsulated grafts in human patients.

Combination Therapies: Synergizing Modalities

No single cell therapy may be sufficient to overcome the robust and multifactorial autoimmune response in T1D. Combination strategies are being explored to achieve synergistic benefits. For instance, co-transplantation of Tregs with SC-islets has been shown to prolong graft survival in animal models. Low-dose IL-2 therapy can boost endogenous Treg numbers and function, complementing ex vivo Treg infusions. Immunomodulatory agents such as anti-CD3 monoclonal antibodies (teplizumab) or anti-thymocyte globulin (ATG) can deplete autoreactive T cells, creating a “tolerant window” for beta cell engraftment. Some trials are combining immunotherapy with beta cell replacement; for example, the Combination Therapy with Treg and Islet Transplant (CTIT) study is evaluating Treg infusion in conjunction with islet transplantation. These combinatorial approaches are likely to be essential for achieving long-term tolerance and functional cure.

Challenges and Considerations

Despite the promise, several significant hurdles must be addressed before cell-based immunotherapy becomes a standard treatment for T1D. Safety is paramount: Treg therapy carries a theoretical risk of excessive immunosuppression, increasing susceptibility to infections and malignancies. Stem cell–derived beta cells must be free of tumorigenic potential and monitored for long-term malignant transformation. The manufacturing of cell products is complex, costly, and requires robust quality control. Reproducibility across batches and scalability to treat large populations remain major industrial challenges. Furthermore, the durability of therapeutic effects is uncertain; Treg persistence wanes over months, and SC-islet grafts may decline due to chronic inflammation or metabolic stress. Patient selection is critical—recent-onset patients with residual beta cell mass are likely to benefit most from immunomodulatory approaches, while those with long-standing disease may require combination therapy. Biomarkers to predict response and guide therapy are still lacking. The high cost of personalized cell therapies also raises questions about equitable access. Ethical and regulatory frameworks for gene-edited cells and combination products are still evolving.

Clinical Trial Landscape and Emerging Data

As of 2025, numerous clinical trials are actively investigating cell-based immunotherapies for T1D. Key studies include:

  • Treg therapy: The T1DAL trial (NCT01210664) and subsequent studies (NCT02773979, NCT04524556) have confirmed safety and provided hints of metabolic preservation. Newer trials are exploring allogeneic “off-the-shelf” Treg products and CAR-Tregs (e.g., NCT05536804).
  • Stem cell–derived beta cells: Vertex’s VX-880 (fully differentiated SC-islets with immunosuppression) has shown promising Phase 1/2 results, with multiple patients achieving insulin independence. VX-264 (immune-evasive SC-islets without immunosuppression) is now in Phase 1/2 (NCT06218056). Other companies like Sernova (with cell pouches) and CRISPR Therapeutics are advancing pipeline candidates.
  • Encapsulation: ViaCyte’s PEC-Encap (NCT02939118) and PEC-Direct (NCT03163511) have provided insights; the latter showed engraftment but required immunosuppression. Next-generation alginate-based capsules are in preclinical stages.
  • Combination therapies: Studies combining Tregs with islet transplantation (e.g., CTIT trial) and using teplizumab plus ATG (NCT02215200) are ongoing.
  • Gene editing: While not yet in clinical trials for T1D, hypoimmunogenic cell lines are being evaluated for in vivo safety in other indications, and translation to T1D is expected soon.

These trials collectively indicate that the field is moving from proof-of-concept to rigorous clinical validation. The next five years will be pivotal in determining whether cell-based immunotherapy can deliver durable functional cures for T1D patients.

Future Directions: Toward a Personalized Cure

The ultimate vision is a personalized, multi-pronged approach that halts autoimmunity and restores endogenous insulin production. Technological advancements in single-cell multi-omics, artificial intelligence, and high-throughput screening will enable the identification of patient-specific immune signatures, leading to tailored therapies. For example, a patient with a strong Treg deficit might receive a combination of Treg infusion and low-dose IL-2, while another with aggressive autoimmunity might benefit from immune-depleting agents followed by transplantation of immune-evasive SC-islets. Portable bioreactors and automated manufacturing platforms may reduce the cost of cell generation, making widespread use feasible. Additionally, preventative strategies are being explored: screening individuals at high genetic risk (e.g., through the TEDDY study) and intervening with cell-based immunotherapy before the onset of symptomatic disease could potentially prevent beta cell loss entirely. The convergence of gene editing, synthetic biology, and regenerative medicine holds the promise of a true cure for type 1 diabetes—one that frees patients from the burden of insulin injections and constant glucose monitoring.

In conclusion, cell-based immunotherapy represents a paradigm shift in the management of type 1 diabetes. By harnessing the power of regulatory immune cells and regenerative stem cell technologies, researchers are making tangible progress toward restoring immune tolerance and functional beta cell mass. While challenges remain, the pace of innovation and the encouraging results from early clinical trials offer renewed hope for millions of people living with this challenging autoimmune disease. Continued investment in research, clinical infrastructure, and regulatory collaboration will be essential to transform these emerging approaches into accessible, durable cures.

For further reading, see the latest reviews in Nature Reviews Endocrinology and JCI Insight, and follow clinical trial updates on ClinicalTrials.gov.